Drug
Replagal (Agalsidase Alfa)
Replagal (Agalsidase Alfa) is a pharmaceutical drug with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
33%(1 trials)
Phase Distribution
Ph phase_2
1
33%
Ph phase_4
1
33%
Ph phase_1
1
33%
Phase Distribution
1
Early Stage
1
Mid Stage
1
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
1(33.3%)
Phase 4Post-market surveillance
1(33.3%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
3 of 3 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(3)
Detailed Status
Completed3
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 11 (33.3%)
Phase 21 (33.3%)
Phase 41 (33.3%)
Trials by Status
completed3100%
Recent Activity
0 active trials
Showing 3 of 3
completedphase_2
Safety Study of Replagal® Therapy in Children With Fabry Disease
NCT01363492
completedphase_1
An Open-Label Maintenance Study of the Enzyme Replacement Therapy Replagal in Patients With Fabry Disease
NCT00357786
completedphase_4
Replagal Enzyme Replacement Therapy for Adults With Fabry Disease
NCT00097890
Clinical Trials (3)
Showing 3 of 3 trials
NCT01363492Phase 2
Safety Study of Replagal® Therapy in Children With Fabry Disease
NCT00357786Phase 1
An Open-Label Maintenance Study of the Enzyme Replacement Therapy Replagal in Patients With Fabry Disease
NCT00097890Phase 4
Replagal Enzyme Replacement Therapy for Adults With Fabry Disease
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3